CR

Gene Biotherapeutics IncOOTC CRXM Stock Report

Last reporting period 31 Dec, 2020

Updated 14 Oct, 2024

Last price

Market cap $B

0.103

Micro

Exchange

OOTC - OTC

CRXM Stock Analysis

CR

Uncovered

Gene Biotherapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.103

Dividend yield

Shares outstanding

64.932 B

Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company is headquartered in San Diego, California. The company went IPO on 2001-07-12. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.

View Section: Eyestock Rating